A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Abali, HuseyinYalcin, SuayibOnal, Huseyin CemDane, FaysalOksuzoglu, BernaOzdemir, NuriyeMertsoylu, Huseyin2024-02-232024-02-2320160732-183X1527-7755https://doi.org/10.1200/jco.2016.34.4_suppl.tps182https://hdl.handle.net/20.500.12452/15083Gastrointestinal Cancers Symposium -- JAN 21-23, 2016 -- San Francisco, CA[Abstract Not Availabe]eninfo:eu-repo/semantics/closedAccess[Keyword Not Available]A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).Conference Object344Q1WOS:000378109600176Q110.1200/jco.2016.34.4_suppl.tps182